OPTIMIZING OUR NON-DILUTIVE FUNDING STRATEGY
Virpax Pharmaceuticals is collaborating with the best drug development minds in the pharmaceutical industry. Our innovative drug delivery platforms have been formulated, so we may optimize how our non-addictive post operative pain, severe pain, and CNS disorder medications are delivered to maximize efficacy.
As part of our ongoing non-dilutive funding strategy, Virpax will work with our banking advisors to pursue sub-licensing, joint ventures, and co-development opportunities with reputable global strategic partners. Virpax will seek University partnerships and grant opportunities. As well, we will continue seeking additional government and military grants and CRADA awards for all of our Rx product candidates.
Partner with us as we seek commercial approval for our next generation non-addictive pain and CNS disorder product candidates.
We can make a difference.
Investor News
July 24, 2024
BUSINESS INQUIRIES
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
610.727.4597
info@virpaxpharma.com
INVESTOR INQUIRIES
Betsy Brod
Affinity Growth Advisors
betsy.brod@affinitygrowth.com
MEDIA INQUIRIES
Public Relations
Virpax Pharmaceuticals, Inc.
pr@virpaxpharma.com